These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 21319970)

  • 1. Circulating tumor cells and plasma DNA analysis in patients with indeterminate early or metastatic breast cancer.
    Shaw JA; Brown J; Coombes RC; Jacob J; Payne R; Lee B; Page K; Hava N; Stebbing J
    Biomark Med; 2011 Feb; 5(1):87-91. PubMed ID: 21319970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients.
    Wallwiener M; Hartkopf AD; Riethdorf S; Nees J; Sprick MR; Schönfisch B; Taran FA; Heil J; Sohn C; Pantel K; Trumpp A; Schneeweiss A
    BMC Cancer; 2015 May; 15():403. PubMed ID: 25972110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker.
    Liu Y; Liu Q; Wang T; Bian L; Zhang S; Hu H; Li S; Hu Z; Wu S; Liu B; Jiang Z
    BMC Cancer; 2013 Apr; 13():202. PubMed ID: 23617715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients.
    Aktas B; Kasimir-Bauer S; Müller V; Janni W; Fehm T; Wallwiener D; Pantel K; Tewes M;
    BMC Cancer; 2016 Jul; 16():522. PubMed ID: 27456970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients.
    Zhang S; Li L; Wang T; Bian L; Hu H; Xu C; Liu B; Liu Y; Cristofanilli M; Jiang Z
    BMC Cancer; 2016 Jul; 16():526. PubMed ID: 27456503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER2 expression on tumor-derived extracellular vesicles and circulating tumor cells in metastatic breast cancer.
    Nanou A; Zeune LL; Bidard FC; Pierga JY; Terstappen LWMM
    Breast Cancer Res; 2020 Aug; 22(1):86. PubMed ID: 32787900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology.
    Somlo G; Lau SK; Frankel P; Hsieh HB; Liu X; Yang L; Krivacic R; Bruce RH
    Breast Cancer Res Treat; 2011 Jul; 128(1):155-63. PubMed ID: 21499685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial.
    Jaeger BAS; Neugebauer J; Andergassen U; Melcher C; Schochter F; Mouarrawy D; Ziemendorff G; Clemens M; V Abel E; Heinrich G; Schueller K; Schneeweiss A; Fasching P; Beckmann MW; Scholz C; Friedl TWP; Friese K; Pantel K; Fehm T; Janni W; Rack B
    PLoS One; 2017; 12(6):e0173593. PubMed ID: 28586395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers characterization of circulating tumour cells in breast cancer patients.
    Nadal R; Fernandez A; Sanchez-Rovira P; Salido M; Rodríguez M; García-Puche JL; Macià M; Corominas JM; Delgado-Rodriguez M; Gonzalez L; Albanell J; Fernández M; Solé F; Lorente JA; Serrano MJ
    Breast Cancer Res; 2012 May; 14(3):R71. PubMed ID: 22554015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel method for downstream characterization of breast cancer circulating tumor cells following CellSearch isolation.
    Frithiof H; Welinder C; Larsson AM; Rydén L; Aaltonen K
    J Transl Med; 2015 Apr; 13():126. PubMed ID: 25896421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of circulating tumor cells (CTCs) with respect to optimal cut-off value and tumor markers in advanced/metastatic breast cancer.
    Shiomi-Mouri Y; Kousaka J; Ando T; Tetsuka R; Nakano S; Yoshida M; Fujii K; Akizuki M; Imai T; Fukutomi T; Kobayashi K
    Breast Cancer; 2016 Jan; 23(1):120-127. PubMed ID: 24906662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
    Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
    Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study.
    Müller V; Riethdorf S; Rack B; Janni W; Fasching PA; Solomayer E; Aktas B; Kasimir-Bauer S; Pantel K; Fehm T;
    Breast Cancer Res; 2012 Aug; 14(4):R118. PubMed ID: 22894854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen receptor expression on circulating tumor cells in metastatic breast cancer.
    Fujii T; Reuben JM; Huo L; Espinosa Fernandez JR; Gong Y; Krupa R; Suraneni MV; Graf RP; Lee J; Greene S; Rodriguez A; Dugan L; Louw J; Lim B; Barcenas CH; Marx AN; Tripathy D; Wang Y; Landers M; Dittamore R; Ueno NT
    PLoS One; 2017; 12(9):e0185231. PubMed ID: 28957377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of circulating tumor cell-specific markers in breast cancer patients using the quantitative RT-PCR assay.
    Wang HY; Ahn S; Kim S; Park S; Jung D; Park S; Han H; Sohn J; Kim S; Lee H
    Int J Clin Oncol; 2015 Oct; 20(5):878-90. PubMed ID: 25708591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of HER2-positive Circulating Tumor Cells Using the LiquidBiopsy System in Breast Cancer.
    Chen W; Zhang J; Huang L; Chen L; Zhou Y; Tang D; Xie Y; Wang H; Huang C
    Clin Breast Cancer; 2019 Feb; 19(1):e239-e246. PubMed ID: 30472074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients.
    Wülfing P; Borchard J; Buerger H; Heidl S; Zänker KS; Kiesel L; Brandt B
    Clin Cancer Res; 2006 Mar; 12(6):1715-20. PubMed ID: 16551854
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Mastoraki S; Strati A; Tzanikou E; Chimonidou M; Politaki E; Voutsina A; Psyrri A; Georgoulias V; Lianidou E
    Clin Cancer Res; 2018 Mar; 24(6):1500-1510. PubMed ID: 29284708
    [No Abstract]   [Full Text] [Related]  

  • 19. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial.
    Larsson AM; Jansson S; Bendahl PO; Levin Tykjaer Jörgensen C; Loman N; Graffman C; Lundgren L; Aaltonen K; Rydén L
    Breast Cancer Res; 2018 Jun; 20(1):48. PubMed ID: 29884204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection and Characterization of Circulating Tumor Associated Cells in Metastatic Breast Cancer.
    Mu Z; Benali-Furet N; Uzan G; Znaty A; Ye Z; Paolillo C; Wang C; Austin L; Rossi G; Fortina P; Yang H; Cristofanilli M
    Int J Mol Sci; 2016 Sep; 17(10):. PubMed ID: 27706044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.